Rein Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein Therapeutics, formerly known as Aileron Therapeutics Inc., is based in AUSTIN, Texas.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-49.87M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.31 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 13.16 |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -63.69% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.12 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.10 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.72 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 86.27M |
| Free Float | 84.97M |
| Market Capitalization | $64.93M |
| Average Volume (Last 20 Days) | 0.47M |
| Beta (Past 60 Months) | 1.37 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 90.89% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |